Vanguard Group
MBVX

Vanguard Group’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Vanguard Group’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-126,592
Closed -$108K – 4210
2018
Q2 		$108K Hold
126,592
– – ﹤0.01% 4045
2018
Q1 		$191K Buy
+126,592
New +$274K ﹤0.01% 3959

Other funds holding MBVX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Vanguard Group's MBVX Position: Q3 2018 in Review

Vanguard Group sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 126,592 shares — an estimated $108K sold.

Vanguard Group first reported a position in MBVX in Q1 2018 and held it in 2 quarters. The position peaked at $191K in Q1 2018. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

  • Vanguard Group reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
  • Vanguard Group sold 126,592 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018, an estimated $108K.
  • Vanguard Group first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q1 2018 and held it in 2 quarters.
  • Vanguard Group's MABVAX THERAPEUTICS HLDGS INC position peaked at $191K in Q1 2018.
  • 2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Vanguard Group's 13F filing for Q3 2018, filed 14 Nov 2018.